Patients receiving optimal medical treatment after MI do not seem to benefit from betablockers in the long term, provided they do not present cardiac failure or systolic function deterioration. This study looked into the cardio protection effect of betablockers (BB) after long term follow up in stable patients with no cardiac failure and a history<a href="https://solaci.org/en/2021/04/13/post-mi-betablockers-for-good/" title="Read more" >...</a>
Less than half of patients undergoing endovascular revascularization for peripheral artery disease to their lower limbs are discharged with optimal medical treatment. Their traditional risk factors are predictors of a more comprehensive treatment; however, women, patients with higher risk of thrombosis, and those more likely to lose a lower limb, are far from being treated<a href="https://solaci.org/en/2021/01/28/optimal-medical-treatment-under-used-in-vascular-peripheral-disease/" title="Read more" >...</a>
In this selection, we summarize for you the most important scientific news of 2020 in the field of pharmacology. 01- Virtual ACC 2020 | Colchicine After Infarction: Good Results and Cost-Effectiveness Low doses of colchicine reduce the risk of ischemic events after an acute myocardial infarction, according to the COLCOT trial, originally presented at the<a href="https://solaci.org/en/2020/12/17/the-most-relevant-articles-in-pharmacology-in-2020/" title="Read more" >...</a>
In this selection, we summarize for you the most important scientific news of 2020 in the field of structural heart disease. 01- Virtual ACC 2020 | COAPT: Better Quality of Life Translates into Harder End-Points After transcatheter mitral valve repair with MitraClip, the COAPT patients saw improved quality of life, better survival rate and fewer hospitalizations<a href="https://solaci.org/en/2020/12/17/the-most-read-articles-in-structural-heart-disease-of-2020/" title="Read more" >...</a>
Transcatheter aortic valve replacement (TAVR) results durable at 5 years to treat failed surgical bioprosthetic valves and at one year to treat valves percutaneously. Regardless the type of the failed valve, the solution is TAVR. The 5 year follow up of the PARTNER 2 valve-in-valve (ViV) showed that TAVR as treatment for failed surgical bioprosthetic<a href="https://solaci.org/en/2020/10/21/tct-2020-tavr-appears-to-be-the-solution-for-all-dysfunctional-biological-valves/" title="Read more" >...</a>
Patients included in the ISCHEMIA trial who had a history of cardiac failure or ventricular function deterioration will benefit from revascularization vs. optimal medical treatment. This is a pre-specified analysis of the paradigmatic ISCHEMIA trial. The ISCHEMIA was published in March 2020 in NEJM and went somewhat unnoticed due to the COVID-19 pandemic. At the<a href="https://solaci.org/en/2020/09/08/esc-2020-revascularization-strategies-ventricular-dysfunction-might-tilt-the-scales/" title="Read more" >...</a>
Early rhythm control therapy in patients recently diagnosed with atrial fibrillation reduces the risk of cardiovascular events compared against the usual treatment of frequency control. These data come from the EAST-AFNET 4 trial recently presented at ESC 2020, simultaneously published in NEJM. These data suggest that we should offer patients early rhythm control therapy to<a href="https://solaci.org/en/2020/09/02/esc-2020-atrial-fibrillation-and-rhythm-control-a-matter-of-time/" title="Read more" >...</a>
Patients with dysfunctional biological prosthetic valves have better outcomes with TAVR vs. surgical reintervention, beyond surgical risk. This study outcomes might even call into question the age cutoff to consider a mechanical vs. a biological prosthesis at first surgery. This analysis recently published in JACC looked at the outcomes of both possible strategies to treat<a href="https://solaci.org/en/2020/08/26/surgical-valve-replacement-might-soon-be-history/" title="Read more" >...</a>
Most young COVID-19 patients not requiring hospitalization showed abnormal cardiac magnetic resonance imaging (CMR) beyond two months after diagnosis. Myocardial injury had been found in more serious cases, but not in a healthy population recovered at home. The increasing evidence of the virus’ capacity to directly affect the heart across the whole population and disease<a href="https://solaci.org/en/2020/08/19/myocardial-injury-for-covid-19-even-in-young-patients-with-mild-symptoms/" title="Read more" >...</a>
The CLASP looked into patients treated with the new device for transcatheter mitral repair called PASCAL and showed low complications rate, high survival rate, significant mitral regurgitation reduction and improved quality of life at one year. In July 2019 we published on our web page the 30 year outcomes of the PASCAL device () which<a href="https://solaci.org/en/2020/07/08/europcr-2020-clasp-new-device-for-mitral-repair-with-at-one-year-follow-up/" title="Read more" >...</a>